Scientific deep-dive

Beyond BMI: Who Actually Needs Treatment

Among people all above BMI 27, ten-year cardiovascular mortality ranged from 5.7% to 0.1%. And in trial participants, weight loss was similar across risk groups, so treating by risk costs nothing in weight lost.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
6 min read·1 citation

Every insurer, every prescriber and every telehealth intake in this market decides who gets treatment using BMI. A study in Nature Medicine built a model from thousands of candidate features and showed what that threshold hides: among people all above a BMI of 27, ten-year cardiovascular mortality ranged from 5.7% to 0.1%.[1] That is a fifty-seven-fold difference, and the number being used cannot see it. How obesity is defined today, BMI cut-offs included, is set out on our obesity condition page.

What the model does

Starting from thousands of tested features, the researchers identified the twenty most informative for predicting the future onset of eighteen obesity complications, and combined them into a single score. It stratified people into risk groups that behaved very differently over ten years, and it generalized to independent populations of both European and non-European ancestry.[1]

Ten-year cardiovascular mortality by risk group, among people with BMI above 27.
Risk groupCardiovascular mortality over 10 years
Highest5.7%
1.8%
Middle0.9%
0.4%
Lowest0.1%

Everyone in that table meets the same BMI criterion. One group faces more than fifty times the risk of another, and the criterion cannot tell them apart.

The finding that should change policy

The researchers then applied the score to participants in the SURMOUNT-1 tirzepatide trial and asked whether baseline risk predicted how well the drug worked.

Weight loss was similar across baseline risk groups.

That sentence from the paper is the one that matters.[1] If the highest-risk people lose about as much weight as the lowest-risk people, then treating by risk rather than by BMI costs nothing in weight lost and should gain a great deal in benefit. The same drug, given to someone facing 5.7% cardiovascular mortality instead of someone facing 0.1%, should do far more good for the same money, although the paper did not test that directly.

Predicted risks also decreased following treatment with tirzepatide. That is a modeled decrease, not a count of observed events.

This bears directly on the rationing fights. Coverage decisions in this market are made on BMI thresholds and cost, and the usual argument is about where to draw the line, which many Asian countries already draw lower, at a BMI of 25. This study suggests the line is drawn on the wrong axis: a BMI cutoff cannot distinguish a fifty-seven-fold difference in risk, and weight loss on the drug was about the same across all of it.

What the study does not establish

  • It is a prediction model, not a treatment trial. It identifies who is at risk. It does not demonstrate that allocating treatment by this score improves outcomes, which would require its own trial.
  • The risk reduction is modeled. “Predicted risks decreased” means the score fell, not that events were counted.
  • Twenty features is still a lot to collect. A score that outperforms BMI only when you have twenty inputs is harder to use than a number from a scale and a tape measure.
  • Three of the authors work for Eli Lilly, which makes tirzepatide. One of them ran the SURMOUNT-1 analysis. The paper states that Lilly did not fund the study.[1]
  • It does not tell an individual what to do. A risk group is a population, and our note on averages applies here as everywhere.

Why BMI persisted anyway

BMI has real strengths. It is free, instant, requires no laboratory, and is calculable by anyone with a scale. That universality is exactly why it became the gate.

Its weaknesses are just as well known. It does not distinguish fat from muscle, distributes differently across populations, and says nothing about where fat sits or what it is doing metabolically. What is new here is a demonstration of how much risk information a BMI threshold discards, and evidence that acting on that information would cost nothing in treatment response.

Frequently Asked Questions

It hides an enormous amount. Among people all above a BMI of 27, ten-year cardiovascular mortality ranged from 5.7% to 0.1% depending on other characteristics. That is a fifty-seven-fold difference the BMI threshold cannot see.
No, and that is the useful part. In SURMOUNT-1 participants, weight loss was similar across baseline risk groups. Since response does not vary much by risk, allocating treatment by risk rather than BMI costs nothing in weight lost and should produce far more benefit, though that has not been tested.
No. It is a prediction model, not a treatment trial. It identifies who is at risk without demonstrating that allocating treatment by the score improves outcomes. That would need its own study.
Predicted risk fell. That means the score decreased, not that events were counted in a follow-up period. It is a modeled improvement rather than an observed one, and the distinction matters.
Because it is free, instant, needs no laboratory and anyone can calculate it. That universality is why it became the gate. What is new here is a measurement of how much risk information the threshold throws away.

References

  1. 1.Demircan K, Carrasco-Zanini J, Williamson A, et al. Data-driven prioritization of high-risk individuals for weight loss interventions Nature Medicine. 2026. PMID: 42062622.

Where to get tirzepatide online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

8.2

bmiMD

Starting below a standard dose, with microdose tiers

8.7

Eden

Coverage in all 50 states, which most sellers will not confirm

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →